BlackRock Health Sciences Trust II
BMEZ · NYSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | -$0 | $0 | $0 |
| % Growth | 6,471% | -102.1% | 10.1% | – |
| Cost of Goods Sold | -$0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 112.6% | 904% | 83.5% | 81.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | -$0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | -$0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Income | -$0 | $0 | $0 | $0 |
| % Margin | -184.2% | -11,976.7% | 47.6% | 68.1% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -92% | -11,969.7% | 47.6% | 68.1% |
| EPS | -1.53 | 3.3 | 0.62 | 0.81 |
| % Growth | -146.4% | 432.3% | -23.5% | – |
| EPS Diluted | -1.53 | 3.3 | 0.62 | 0.81 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -91.9% | -11,976.7% | 47.6% | 68.1% |